United States v. Little

314 F. Supp. 3d 647
CourtDistrict Court, E.D. Pennsylvania
DecidedJuly 9, 2018
DocketCRIMINAL NO. 13–582–01; CRIMINAL NO. 13–582–02
StatusPublished

This text of 314 F. Supp. 3d 647 (United States v. Little) is published on Counsel Stack Legal Research, covering District Court, E.D. Pennsylvania primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
United States v. Little, 314 F. Supp. 3d 647 (E.D. Pa. 2018).

Opinion

Rufe, District Judge.

*650At the end of an 18-day trial, a jury convicted Defendants Leon Little and Colise Harmon of conspiracy to distribute oxycodone and alprazolam, and related substantive offenses. Little moves for a judgment of acquittal or, in the alternative, a new trial, pursuant to Federal Rules of Criminal Procedure 29 and 33 with respect to all fifty counts on which he was convicted. Harmon moves for acquittal or a new trial with respect to the conspiracy count only. For the reasons that follow, the motions will be denied.

I. BACKGROUND

In November of 2011, agents from the Drug Enforcement Administration ("DEA") noticed a greater-than-60-fold increase since 2009 in orders of oxycodone products from a small drugstore in downtown Philadelphia, Philly Pharmacy.1 After further investigation, DEA agents observed that a large number of the prescriptions filled at the pharmacy came from Dr. Laurence Browne, a physician with a small medical office in suburban Philadelphia, and that multiple prescriptions for oxycodone products from Dr. Browne's office were being filled sequentially, indicating that patients from the office arrived at the pharmacy together.2 Video surveillance at Philly Pharmacy showed groups of patients arriving and departing via a GMC Yukon Denali nearly on a daily basis.3 Subsequent GPS tracking of the vehicle showed that it traveled routinely between Dr. Browne's office, the pharmacy, and the Raymond Rosen Projects,4 an affordable housing community in North Philadelphia.5 A review of the DEA's prescription monitoring program database showed that two other local pharmacies, Northeast Pharmacy and Pharmacy of America, also had filled oxycodone prescriptions from Dr. Browne's office, and that patients had presented duplicate prescriptions for the same medications on the same day at more than one pharmacy.6 Based on additional investigation, the Government interviewed and later charged over 60 individuals in connection with a scheme in which "pseudo-patients" were recruited and paid to obtain and fill prescriptions for oxycodone and other drugs, which were then collected for illicit drug sales. The majority of these defendants entered into plea agreements with the Government, pursuant to which they agreed to act as cooperating witnesses against others in the scheme.

Most of these cooperating witnesses had served as pseudo-patients, and many of them identified Defendant Little as the leader of the drug scheme and Defendant Harmon as a key player. Two of these witnesses, James Alexander and John Baldwin, admitted to recruiting additional patients to the scheme and acting as "drivers" by transporting patients and pills at Little's request. Alexander, Baldwin, and others identified Harmon as another driver who handled patients, pills, and money for the scheme. Among other witnesses, the Government also obtained testimony from *651Heather Herzstein, the receptionist at Dr. Browne's office who admitted to scheduling appointments for pseudo-patients in exchange for cash payments from Little; Brendin Strand, a Delaware-based drug dealer who admitted to purchasing and re-selling oxycodone pills from Little; and Aminah Shabazz, Little's romantic and business partner, who described multiple financial transactions she executed in support of the couple's plan to open a United Postal Service ("UPS") franchise using cash from the pill scheme.

Little and Harmon were first indicted by a federal grand jury on October 23, 2013 for conspiracy to distribute oxycodone and alprazolam, and related charges. The Third Superseding Indictment charged Little with one count of conspiracy to distribute oxycodone and alprazolam (a controlled anxiolytic substance sold under the brand name Xanax) between June 2010 and August 2012 in violation of 21 U.S.C. § 846 (Count 1); 24 counts of distributing, and aiding and abetting distribution of, oxycodone in violation of 21 U.S.C. §§ 841(a)(1), (b)(1)(C) and 18 U.S.C. § 2 (Counts 2-10, 16-30); nine counts of acquiring, and aiding and abetting in acquiring, oxycodone by fraud using forged prescriptions in violation of 21 U.S.C. §§ 843(a)(3) and 18 U.S.C. § 2 (Counts 11-15, 31-34); one count of engaging in an unlawful monetary transaction by purchasing a motorcycle using illegal drug proceeds in violation of 18 U.S.C. §§ 1957 and 2 (Count 35); and 15 counts of money laundering, and aiding and abetting and willfully causing money laundering, in connection with the transfer of illegal drug proceeds into multiple third party bank accounts in violation of 18 U.S.C. §§ 1956(a)(1)(B)(i) and 2 (Counts 36-50).7 Harmon was charged with one count of conspiracy to distribute oxycodone and alprazolam (Count 1), 15 counts of distributing oxycodone, and aiding and abetting (Counts 16-30), and four counts of acquiring oxycodone by fraud, and aiding and abetting (Counts 31-34).8

Defendants' jury trial began on November 29, 2016. Over the course of 13 days, the Government introduced testimony from more than two dozen witnesses, including Alexander, Baldwin, other pseudo-patients, Herzstein, Strand, Shabazz, relatives and friends of Shabazz who participated in the money laundering transactions, Little's ex-wife, the former owner of Northeast Pharmacy, an employee at a motorcycle dealer in Bensalem, Pennsylvania, a former vice president at the Sugar House Casino frequented by Little, agents from the DEA and Internal Revenue Service ("IRS"), and local law enforcement officers. The Government also presented more than 200 exhibits, including call logs and recordings, surveillance footage and pictures, GPS location data, prescription records, patient files, appointment books, sales records, records of financial transactions, and other documents.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

United States v. Mercado
610 F.3d 841 (Third Circuit, 2010)
United States v. Stillis
437 F. App'x 78 (Third Circuit, 2011)
United States v. Robert Craig Wexler
838 F.2d 88 (Third Circuit, 1988)
United States v. Darrin Casper, A/K/A Barry Jackson
956 F.2d 416 (Third Circuit, 1992)
United States v. Aaron Keith Lovett
964 F.2d 1029 (Tenth Circuit, 1992)
United States v. Mark Iafelice
978 F.2d 92 (Third Circuit, 1992)
United States v. Charles William Kunzman
54 F.3d 1522 (Tenth Circuit, 1995)
United States v. Robert E. Brennan
326 F.3d 176 (Third Circuit, 2003)
United States v. Stefan E. Brodie
403 F.3d 123 (Third Circuit, 2005)
United States v. Gary Wasserson
418 F.3d 225 (Third Circuit, 2005)
United States v. Sherman Bobb
471 F.3d 491 (Third Circuit, 2006)
United States v. Kemp
500 F.3d 257 (Third Circuit, 2007)
United States v. Boria
592 F.3d 476 (Third Circuit, 2010)
United States v. Cunningham
517 F.3d 175 (Third Circuit, 2008)

Cite This Page — Counsel Stack

Bluebook (online)
314 F. Supp. 3d 647, Counsel Stack Legal Research, https://law.counselstack.com/opinion/united-states-v-little-paed-2018.